callithrix
jacchu
common
marmoset
one
primit
nonhuman
primat
speci
use
wide
fundament
biolog
pharmacolog
toxicolog
studi
marmoset
breed
well
captiv
good
reproduct
effici
sexual
matur
reach
within
month
age
allow
rapid
expans
coloni
earli
avail
sexual
matur
anim
permit
earlier
assess
product
candid
adult
rel
small
size
allow
reduct
materi
requir
lead
reduct
develop
time
cost
fewer
anim
also
requir
due
abil
use
pharmacolog
toxicolog
nonclin
studi
factor
alongsid
better
understand
optim
nutrient
welfar
requir
recent
year
facilit
gener
cohes
robust
dataset
growth
biotechnologyderiv
pharmaceut
nonhuman
primat
use
necess
also
increas
nevertheless
also
grow
public
call
minim
use
util
primit
marmoset
speci
may
provid
optim
compromis
scientif
rational
care
consid
use
justifi
sever
advantag
use
marmoset
model
nonclin
develop
pharmaceut
product
evalu
human
volunt
patient
clinic
studi
investig
medicin
product
imp
eg
pharmaceut
includ
biotechnolog
deriv
product
gene
therapi
vaccin
requir
evalu
nonclin
toxicolog
safeti
studi
gener
rodent
nonrod
second
speci
nonclin
toxicolog
safeti
studi
allow
risk
assess
perform
act
safeguard
human
subject
use
nonrod
speci
addit
rodent
speci
aim
limit
uncertainti
extrapol
process
anim
toxic
safeti
data
human
situat
dog
specif
circumst
minipig
frequent
use
nonrod
speci
howev
scientif
justifi
inappropri
regulatori
author
worldwid
accept
use
nonhuman
primat
nonhuman
primat
also
use
repres
wellestablish
model
compound
class
relev
speci
especi
biotechnologyderiv
product
detect
known
side
effect
upon
specif
recommend
regulatori
author
new
world
monkey
callithrix
jacchu
common
marmoset
larger
old
world
monkey
macaca
fasciculari
cynomolgu
monkey
macaca
mulatta
rhesu
monkey
typic
use
weatheral
scher
paper
provid
gener
overview
marmoset
model
nonclin
develop
pharmaceut
product
take
account
recent
regulatori
chang
husbandri
new
micro
sampl
technolog
requir
reduc
primat
use
alongsid
contrast
need
relev
speci
select
biotechnolog
deriv
product
develop
regulatori
author
worldwid
recogn
use
marmoset
nonclin
develop
one
primit
nonhuman
primat
speci
phylogenet
distant
human
use
requir
less
ethic
justif
larger
old
world
monkey
homeoffic
marmoset
rel
small
anim
approxim
size
adult
rat
g
tabl
small
size
sever
advantag
earli
phase
imp
develop
elsevi
inc
materi
product
usual
suboptim
therefor
suffici
quantiti
rate
limit
studi
sinc
amount
materi
requir
roughli
proport
size
anim
signific
save
cost
time
use
smaller
speci
marmoset
reduct
materi
requir
estim
compar
g
marmoset
kg
macaqu
weatheral
zuhlk
weinbauer
smith
et
al
shorter
synthesi
time
offer
potenti
earlier
administr
human
subject
turn
may
lead
substanti
cost
save
estim
rang
month
reduct
develop
time
reduct
amount
materi
requir
earli
develop
studi
may
also
correspond
benefit
allow
time
larg
scale
synthesi
optim
opportun
benefit
time
cost
later
develop
smith
et
al
marmoset
also
requir
smaller
cage
larger
nonhuman
primat
mani
methodolog
technolog
use
rat
also
use
marmoset
metabol
cage
past
certain
circumst
small
size
consid
potenti
hurdl
larger
volum
blood
need
pharmacokinet
toxicokinet
investig
result
increas
number
anim
requir
consequ
increas
materi
requir
cost
nowaday
need
larg
blood
volum
diminish
avail
sensit
analyt
techniqu
dri
spot
detect
newer
clinic
patholog
techniqu
enzym
link
immuno
assay
elisa
kit
pastori
et
al
dunbar
hu
wang
http
wwwsfbrorgsnprcdetailaspx
marmoset
breed
well
captiv
nowaday
nearli
marmoset
use
captiv
bred
sometim
f
gener
provid
reproduc
dataset
scher
marmoset
high
reproduct
effici
typic
produc
twin
twice
year
sexual
matur
reach
within
month
age
compar
approxim
year
old
world
monkey
aspect
particularli
import
issu
toxic
studi
conduct
nonrod
speci
anim
sexual
matur
consider
concern
high
reproduct
effici
also
allow
rapid
establish
inhous
breed
coloni
easier
avail
anim
reliabl
result
due
reduc
stress
transport
coloni
alter
secondari
benefit
reduct
overal
cost
furthermor
life
cycl
marmoset
physiolog
faster
year
old
world
monkey
result
greater
avail
age
anim
import
aspect
studi
involv
age
bone
diseas
marmoset
born
natur
occur
chimera
although
anim
genet
distinct
share
toler
cell
niblack
et
al
ross
et
al
natur
chimer
enabl
studi
cell
transfer
without
initi
allorespons
mansfield
et
al
marmoset
arbor
diurnal
speci
origin
south
american
forest
suitabl
environ
diet
requir
reflect
natur
habitat
natur
behavior
marmoset
indic
captiv
environ
degre
complex
stimul
due
arbor
natur
volum
avail
space
vertic
height
enclosur
appear
import
floor
area
badihi
et
al
european
guidelin
hous
recommend
follow
marmoset
hous
group
studi
pair
cage
construct
height
least
top
cage
least
floor
minimum
floor
area
breed
pair
famili
group
rich
complex
environ
includ
opportun
climb
forag
eg
via
puzzl
feeder
high
cage
gnaw
swing
social
play
well
rest
place
provid
cage
equip
wooden
bar
hide
provis
take
account
marmoset
use
arbor
habitat
import
provid
certain
degre
variabl
orient
diamet
firm
allow
anim
perform
appropri
locomotor
jump
behavior
weatheral
fig
fig
marmoset
frequent
scentmark
environ
total
remov
familiar
scent
may
caus
behavior
problem
altern
clean
sanit
enclosur
enrich
devic
retain
territori
scentmark
regular
handl
human
contact
benefici
improv
anim
habitu
monitor
experiment
condit
facilit
train
cooper
procedur
sinc
marmoset
origin
tropic
rain
forest
kept
rel
high
temperatur
rel
humid
light
dark
cycl
h
recommend
light
sourc
illumin
uniformli
hold
room
howev
within
anim
enclosur
shade
area
alway
provid
special
consider
given
minim
exposur
ultrasound
sudden
unexpect
nois
within
hear
rang
marmoset
unit
state
nation
research
council
guid
care
use
laboratori
anim
integr
recent
publish
data
scientif
principl
expert
opinion
recommend
practic
human
care
use
anim
research
test
teach
nation
research
council
guid
intern
accept
primari
refer
anim
care
scientif
commun
previou
edit
serv
basi
accredit
institut
worldwid
associ
minimum
space
base
need
pair
group
hous
marmoset
howev
group
composit
critic
consid
cage
minimum
height
least
cm
minimum
floor
area
breed
pair
howev
recommend
highlight
light
marmoset
arbor
natur
taller
cage
util
speciesspecif
environment
psycholog
enrich
nation
research
council
marmoset
climat
toler
monogami
prefer
live
small
famili
group
make
compar
straightforward
provid
hous
husbandri
meet
anim
need
promot
wellb
signific
advantag
larger
nonhuman
primat
consider
difficult
provid
laboratori
hous
due
larger
physic
size
also
greater
natur
troop
home
rang
size
social
characterist
includ
complex
domin
relationship
aggress
tendenc
baskervil
coupl
physic
microbiolog
health
hazard
larger
nonhuman
primat
pose
human
well
climat
requir
cynomolgu
monkey
suggest
husbandri
marmoset
one
major
advantag
provid
accept
qualiti
life
laboratori
anim
ethic
perspect
sever
benefit
use
marmoset
characterist
facilit
provis
complex
enrich
environ
less
destruct
larger
nonhuman
primat
greater
wellb
environ
also
translat
consist
reliabl
result
last
decad
extens
databas
also
gener
within
compani
toxicolog
servic
provid
breed
establish
provid
essenti
background
data
support
abbott
smith
et
al
marmoset
eat
fresh
fruit
bread
loaf
egg
nut
high
protein
intak
commerci
supplement
also
avail
eg
new
world
monkey
prepar
diet
harlan
teklad
biscuit
condens
milk
also
typic
use
remuner
food
rtc
spa
intern
procedur
marmoset
high
requir
protein
sinc
unabl
synthes
vitamin
without
access
uvb
radiat
diet
must
also
supplement
adequ
level
vitamin
continu
improv
diet
well
husbandri
environment
enrich
help
dramat
reduc
incid
marmoset
wast
syndrom
tucker
result
gener
consist
reproduc
dataset
clinic
examin
vivo
laid
regulatori
guidelin
feasibl
establish
reproduc
marmoset
marmoset
gentli
restrain
rel
easi
experienc
staff
take
blood
sampl
anim
give
inject
howev
marmoset
small
allow
larg
number
sampl
taken
individu
pharmacokinetictoxicokinet
clinic
patholog
studi
blood
sampl
usual
taken
femor
vein
although
tail
vein
use
small
toxicokinet
sampl
typic
circul
blood
volum
remov
within
one
month
requir
sensit
analyt
method
develop
small
sampl
size
similar
rodent
smith
et
al
zuhlk
weinbauer
consequ
marmoset
small
size
pose
problem
analyt
methodolog
alreadi
place
rodent
furthermor
volum
blood
requir
pharmacokinetictoxicokinet
analysi
significantli
reduc
develop
dri
spot
blood
detect
circumst
pastori
et
al
small
size
marmoset
allow
collect
urin
use
metabol
cage
similar
use
rodent
elimin
addit
difficulti
associ
use
larger
nonhuman
primat
examin
eye
may
perform
without
sedat
abnorm
anticip
routin
find
hyaloid
arteri
remnant
young
anim
screen
compound
ototox
perform
sedat
marmoset
use
brainstem
auditori
evok
respons
monitor
hear
loss
eg
loop
diuret
aminoglycosid
antibiot
kuzel
et
al
screen
potenti
effect
cardiovascular
system
import
compon
safeti
pharmacolog
repeat
dose
toxicolog
studi
determin
restrain
sedat
marmoset
speci
inform
data
obtain
remot
telemetri
schnell
wood
also
monitor
motor
activ
bodi
temperatur
marmoset
wellestablish
laboratori
speci
mani
review
patholog
chang
report
long
ago
earli
databas
collect
marmoset
patholog
experi
continu
within
number
establish
marmoset
rang
background
patholog
speci
experi
need
interpret
lesion
found
cours
toxicolog
studi
broadmeadow
zuhlk
weinbauer
smith
et
al
propos
dose
rout
human
determin
dose
rout
test
speci
oral
intraven
intramuscular
subcutan
intranas
intraderm
intraperiton
feasibl
marmoset
oral
gavag
common
method
dose
way
rubber
cathet
intraven
dose
commonli
perform
use
saphen
vein
although
laboratori
success
employ
cephal
vein
experienc
technician
daili
intraven
dose
perform
rel
easili
well
continu
intraven
infus
ruiz
de
elvira
abbott
repeat
intraven
dose
latter
use
subcutan
implant
vascular
access
port
smith
et
al
zuhlk
weinbauer
intramuscular
inject
usual
given
thigh
muscl
subcutan
inject
made
upper
back
abdomen
combin
lightweight
backpack
system
smith
et
al
zuhlk
weinbauer
dietari
administr
nonpalat
product
inhal
dose
method
present
challeng
inhal
studi
possibl
provid
mask
marmoset
similar
fashion
use
macaqu
howev
small
size
make
difficult
one
month
repeat
inhal
studi
describ
use
whole
bodi
exposur
anim
expos
h
per
day
vapor
kurata
et
al
marmoset
use
success
number
pharmaceut
biotechnolog
compani
support
clinic
trial
product
registr
unit
state
us
food
drug
administr
fda
european
medicin
agenc
ema
zuhlk
weinbauer
smith
et
al
european
union
distinguish
six
nonclin
categori
experi
use
marmoset
may
conduct
commis
european
commun
follow
biolog
studi
fundament
natur
research
develop
qualiti
control
product
devic
human
medicin
dentistri
veterinari
medicin
toxicolog
safeti
evalu
diagnosi
diseas
educ
train
distribut
test
accord
categori
outlin
tabl
commis
european
commun
abil
marmoset
util
fundament
biolog
pharmacolog
pharmacodynam
pharmacokinet
toxicolog
studi
allow
strong
interconnect
relationship
disciplin
lead
reduc
number
anim
use
complet
data
set
lower
cost
eg
need
repeat
dose
rang
studi
less
pharmacokinetictoxicokinet
anim
requir
less
materi
requir
develop
time
reduc
marmoset
use
wide
field
neural
cognit
scienc
immunolog
infecti
diseas
reproduct
biolog
stem
cell
research
due
close
genet
physiolog
metabol
similar
human
mansfield
et
al
activ
center
understand
fundament
element
human
biolog
well
pathogenesi
diseas
syndrom
human
provid
relev
translat
research
potenti
new
medicin
recent
sever
intern
activ
implement
support
use
marmoset
nonclin
develop
pharmaceut
includ
biotechnolog
deriv
product
gene
therapi
vaccin
includ
follow
signific
progress
marmoset
genom
sequenc
mansfield
et
al
http
ucscbrows
success
creation
marmoset
specif
dna
microarray
public
avail
larg
collect
express
sequenc
tag
est
marmoset
origin
genbank
http
creation
transgen
marmoset
cyranoski
sasaki
et
al
marmoset
key
pharmacodynam
model
field
neurosci
immunolog
infecti
diseas
also
serv
use
model
diseas
area
tabl
marmoset
wide
use
model
number
neurolog
disord
includ
multipl
sclerosi
parkinson
diseas
huntington
diseas
mansfield
et
al
well
studi
normal
neurophysiolog
brysch
et
al
hornung
et
al
guldin
et
al
peretta
multipl
sclerosi
chronic
progress
autoimmun
diseas
brain
spinal
cord
rumril
experiment
autoimmun
encephalomyel
eae
model
marmoset
repres
chronic
relaps
multipl
sclerosi
genain
hauser
hart
et
al
merkler
et
al
wherea
eae
model
rodent
rhesu
monkey
reminisc
acut
dissemin
encephalomyel
sever
nonclin
studi
success
conduct
eae
marmoset
model
use
vivo
magnet
reson
imag
mri
visual
evok
potenti
neuropatholog
measur
efficaci
boretiu
et
al
diem
et
al
hart
massacesi
new
potenti
therapeut
antibodi
human
cluster
differenti
cd
share
subunit
interleukin
success
test
eae
marmoset
model
boon
et
al
hart
et
al
parkinson
diseas
pd
neurodegen
diseas
character
insuffici
product
dopamin
substantia
nigra
area
brain
lead
signific
impair
movement
dawson
dawson
marmoset
recogn
model
parkinson
diseas
owen
et
al
use
select
neurotoxin
destroy
dopamin
neuron
toxin
commonli
use
mptp
recent
transgen
model
disord
develop
marmoset
lead
overexpress
protein
asynuclein
use
viral
vector
kirik
et
al
eslamboli
et
al
experiment
use
marmoset
import
intermediari
step
rodent
studi
control
clinic
trial
phylogenet
similar
human
pivot
assess
optim
efficaci
candid
therapi
howev
marmoset
suitabl
nonhuman
primat
speci
use
specif
behavior
test
requir
eg
cognit
test
tremor
rate
eslamboli
huntington
diseas
hd
fatal
genet
neurodegen
disord
anim
model
fall
two
broad
categori
nongenet
eg
quinolin
acid
qa
transgen
histor
former
domin
field
hd
research
ramaswami
et
al
unilater
qa
putamen
lesion
marmoset
provid
use
recogn
tool
investig
potenti
treatment
kendal
et
al
howev
model
replic
patholog
symptom
hd
rather
develop
consist
reproduc
lesion
motor
impair
kendal
et
al
kendal
et
al
recent
marmoset
huntingtin
htt
gene
isol
identifi
result
potenti
prepar
transgen
hd
marmoset
model
could
provid
inform
underli
patholog
abil
test
therapeut
candid
gene
therapi
hohjoh
et
al
ramaswami
et
al
develop
imp
critic
import
potenti
effect
immun
system
either
intend
pharmacodynam
result
toxicolog
effect
investig
appropri
model
nonhuman
primat
typic
consid
superior
model
investig
immunolog
pharmacodynam
potenti
immun
toxic
effect
imp
weatheral
marmoset
key
speci
sever
reason
marmoset
repres
uniqu
speci
studi
b
cellmedi
diseas
born
natur
occur
bone
marrow
chimera
niblack
et
al
larg
varieti
surfac
receptor
lymphocyt
blood
cell
found
crossreact
monoclon
antibodi
correspond
human
epitop
indic
high
degre
similar
speci
barton
et
al
neubert
et
al
rieck
et
al
kireta
et
al
kametani
et
al
sever
studi
perform
result
gener
data
bank
anim
largest
data
bank
avail
surfac
receptor
neubert
et
al
howev
marmoset
human
qualit
quantit
differ
exist
respect
surfac
marker
lymphocyt
relev
studi
immunotox
marmoset
lack
natur
killer
cell
typic
marker
found
human
convers
cytotox
killer
effector
cell
found
marmoset
found
human
neubert
et
al
marmoset
use
extens
infecti
diseas
research
due
larg
part
uniqu
sensit
number
virus
bacteria
parasit
respons
human
infecti
diseas
mansfield
et
al
furthermor
era
bioterror
becom
realiti
increas
demand
nonhuman
primat
model
regulatori
author
establish
new
guidelin
test
vaccin
therapeut
pathogen
govern
determin
potenti
biolog
weapon
marmoset
also
use
investig
absorpt
distribut
metabol
excret
new
imp
addit
techniqu
practic
larger
nonhuman
primat
wholebodi
autoradiographi
perform
marmoset
broadmeadow
furthermor
marmoset
repres
key
model
imp
substrat
cytochrom
investig
glucuronid
vitro
constitut
express
high
level
human
liver
play
import
role
mutagen
activ
heterocycl
amin
butler
et
al
shimada
et
al
also
constitut
express
liver
marmoset
edward
et
al
bullock
et
al
cynomolgu
monkey
furthermor
marmoset
human
respond
similar
induc
appear
similar
control
mechan
sakuma
et
al
constitut
largest
fraction
human
hepat
involv
metabol
medicin
current
use
koehler
et
al
broad
substrat
specif
repres
basi
mani
clinic
relev
medicinemedicin
interact
marmoset
key
model
studi
metabol
interact
strong
similar
marmoset
human
gene
protein
function
mcarthur
et
al
nelson
et
al
william
et
al
koehler
et
al
tabl
uridin
diphosph
glucuronosyltransferas
ugt
larg
famili
membran
bound
enzym
respons
detoxif
wide
rang
xenobiot
endogen
compound
larg
number
product
glucuronid
whether
directli
follow
phase
step
necessit
thorough
understand
glucuronid
effici
pharmaceut
develop
dutton
typic
rodent
use
primari
anim
model
dog
commonli
use
second
anim
model
pharmacokinet
studi
howev
wide
rang
product
extens
glucuronid
dog
liver
microsom
compar
human
hepat
microsom
soar
et
al
furthermor
qualit
differ
glucurond
observ
dog
human
extrahepat
glucuronid
markedli
reduc
dog
soar
et
al
contrast
quantit
qualit
similar
human
marmoset
glucuronid
vitro
marmoset
use
model
especi
rate
pathway
glucuronid
medicin
known
differ
significantli
rodent
dog
human
soar
et
al
signific
extrahepat
eg
kidney
glucuronid
observ
marmoset
comparison
anim
merit
use
preclin
pharmacokinet
safeti
evalu
studi
nevertheless
work
also
perform
confirm
observ
differ
speci
vitro
accur
repres
situat
vivo
soar
et
al
toxicolog
safeti
evalu
repres
largest
use
marmoset
nonclin
develop
typic
use
acut
subacut
chronic
toxicokinet
studi
commis
european
commun
interestingli
long
term
studi
year
durat
also
report
smith
et
al
tabl
marmoset
use
pharmacolog
well
toxicolog
studi
addit
wellestablish
class
compound
marmoset
may
well
offer
altern
speci
dog
show
hypersensit
idiosyncrasi
smith
et
al
gaudi
et
al
tabl
marmoset
repres
use
model
investig
teratolog
potenti
pharmaceut
investig
aspect
reproduct
physiolog
immunecontracept
due
earli
sexual
matur
high
reproduct
effici
similar
placent
human
mansfield
et
al
tabl
contrast
sever
aspect
reproduct
process
marmoset
exhibit
discrep
describ
human
cline
luetjen
et
al
zuhlk
weinbauer
differ
femal
includ
multiovul
postpartum
concept
lack
extern
sign
menstruat
male
includ
alter
even
absenc
gene
known
essenti
reproduct
develop
durat
menstrual
cycl
marmoset
vari
averag
day
unlik
women
luteal
phase
compar
long
expens
follicular
phase
egg
ovul
midphas
follicl
stimul
hormon
fsh
peak
presenc
multipl
domin
follicl
marmoset
repres
anoth
differ
human
zuhlk
weinbauer
juvenil
toxicolog
studi
use
background
data
gener
marmoset
year
examin
differ
clinic
patholog
endpoint
organ
weight
young
adult
marmoset
wadsworth
et
al
davi
et
al
tabl
summari
marmoset
characterist
characterist
domin
hepat
protein
marmoset
sequenc
similar
human
marmoset
across
first
kb
clone
promot
marmoset
gene
cluster
human
gene
rodent
gene
form
sever
separ
cluster
mcarthur
et
al
nelson
et
al
william
et
al
marmoset
cdna
exhibit
high
similar
human
gene
william
et
al
enzymat
activ
similar
koehler
et
al
scientif
rational
care
consid
use
nonrod
speci
justifi
consider
advantag
use
marmoset
model
pharmaceut
product
develop
rang
reduc
materi
requir
due
small
size
fold
less
predict
acceler
develop
month
faster
earlier
assess
product
candid
adult
due
earli
sexual
matur
reduc
number
anim
requir
due
abil
use
pharmacolog
toxicolog
studi
factor
alongsid
better
understand
optim
nutrient
welfar
requir
recent
year
facilit
gener
cohes
robust
dataset
growth
biotechnologyderiv
product
gene
therapi
use
nonhuman
primat
necess
also
increas
sinc
often
relev
speci
provid
adequ
safeti
assess
nevertheless
grow
public
call
minim
use
futur
util
primit
marmoset
speci
may
provid
optim
compromis
tabl
compound
class
marmoset
may
suitabl
model
dog
class
compound
marmoset
may
suitabl
model
dog
vomit
morphin
compound
atrioventricular
block
calcium
antagonist
reflex
tachycardia
antihypertens
allerg
reaction
vehicl
cremophor
tabl
exampl
marmoset
use
teratolog
reproduct
studi
higher
nonhuman
primat
cynomolgu
rhesu
monkey
gener
time
year
make
multigener
studi
impract
howev
multigener
studi
feasibl
marmoset
compar
short
gener
time
month
marshal
et
al
investig
mechan
thalidomid
teratogenesi
metabolit
thalidomid
may
caus
downregul
surfac
adhes
receptor
therebi
alter
cell
cell
cell
extracellular
matrix
interact
within
develop
limb
bud
heger
et
al
heger
et
al
klug
et
al
neubert
et
al
examin
effect
lutein
hormon
follicular
stimul
hormon
granulosa
cell
develop
steroidogenesi
barrett
millar
et
al
hillier
et
al
defin
mechan
estradiol
inactiv
vitro
fertil
embryo
transfer
parthenogenesi
husen
et
al
summer
et
al
marshal
et
al
marshal
et
al
marshal
et
al
luetjen
wesselmann
determin
whether
infant
feed
soya
formula
milk
contain
high
level
plant
estrogen
pose
immedi
longerterm
health
risk
develop
testi
reproduct
system
male
initi
studi
found
testosteron
level
suppress
anim
fed
soya
formula
milk
longer
term
followup
analysi
anim
indic
infant
feed
soya
formula
milk
gross
reproduct
effect
male
marmoset
alter
testi
size
cell
composit
author
conclud
similar
chang
like
occur
adult
men
fed
soya
formula
milk
infant
sharp
et
al
tan
et
al
matsumoto
et
al
lipid
lower
agent
fibrat
eg
ciprofibr
clofibr
oral
sever
studi
year
fibrat
hypolipidaem
agent
chronic
studi
rat
mice
produc
tumor
preneoplast
chang
predict
human
clofibr
ciprofibr
toxic
studi
year
durat
conduct
two
laboratori
shown
marmoset
predict
human
marmoset
studi
unlik
rodent
induct
liver
tumor
eason
et
al
spencer
et
al
smith
et
al
reddi
et
al
makowska
et
al
graham
et
al
non
steroid
antiinflammatori
indomethacin
oral
week
nonsteroid
antiinflammatori
reduc
fever
pain
stiff
swell
inhibit
prostaglandin
releas
oberto
et
al
parkinson
diseas
ropinirol
oralsafeti
studi
ropinirol
microgramkg
dose
produc
signific
decreas
number
postur
signific
increas
time
spent
cage
front
human
threat
test
rodent
effect
seen
mgkg
eden
et
al
psychot
disord
includ
schizophrenia
clozapin
oral
intramuscularsafeti
studi
clozapin
wide
dose
rang
unlik
antipsychot
increas
motiv
state
marmoset
suggest
uniqu
clinic
profil
cilia
et
al
vari
thalidomid
marmoset
use
comprehens
investig
mechan
thalidomid
teratogenesi
heger
et
al
neubert
et
al
